Skip to content

Orphan Drugs Industry Advisory & Intelligence

Big (bio)pharma involvement and orphan diseases: reality or “orphan-washing”? Part 2 – The Pfizer case

Posted on May 2, 2016May 2, 2016 by christian@orphandrugsindustry.com

Link to article

Share this:

  • Twitter
  • Facebook
  • LinkedIn
  • Print
  • Reddit
  • Tumblr
  • Email
  • Pinterest
  • Pocket
Posted in PulseTagged Big pharma, Orphan drugs, Rare diseases

Post navigation

← Big (bio)pharma involvement and orphan diseases: reality or “orphan-washing”? Part 1 – The Novartis case
Just started a vertical consulting practice focused on Inborn Errors of Metabolism (IEMs) →

Headquarter

1, rue Roch ar Ruguel
29680 Roscoff, France
Tel: +33 (0)6 67 26 60 92
Create a website or blog at WordPress.com
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.